Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response

Abstract : PI-2301 is an immunomodulator that could be an alternative therapy for MS. A placebo-controlled, multiple-ascending dose, double-blind study was performed in patients with secondary-progressive MS. Treatment was given subcutaneously once weekly for 8 weeks, followed by a 4-week open-label treatment period with active drug. The most common adverse event was transient injection site reactions. Non-significant trend for increases in serum levels of IL-3, IL-13, and CCL22 over time were suggestive of a beneficial T(H)2 immune response in subjects dosed with PI-2301 at 3 and 10 mg. MRI data indicated a non-significant trend for a reduction of lesion numbers in subjects treated with 1 and 3 mg PI-2301. (C) 2010 Elsevier B.V. All rights reserved.
Document type :
Journal articles
Complete list of metadatas

Cited literature [38 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01874527
Contributor : Laurent Jonchère <>
Submitted on : Thursday, September 20, 2018 - 2:17:06 PM
Last modification on : Thursday, February 14, 2019 - 4:41:19 PM
Long-term archiving on : Friday, December 21, 2018 - 3:28:31 PM

File

Kovalchin et al_2010_Results o...
Files produced by the author(s)

Identifiers

Citation

J. Kovalchin, J. Krieger, M. Genova, K. Collins, M. Augustyniak, et al.. Results of a phase I study in patients suffering from secondary-progressive multiple sclerosis demonstrating the safety of the amino acid copolymer PI-2301 and a possible induction of an anti-inflammatory cytokine response. Journal of Neuroimmunology, Elsevier, 2010, 225 (1-2), pp.153-163. ⟨10.1016/j.jneuroim.2010.04.008⟩. ⟨hal-01874527⟩

Share

Metrics

Record views

31

Files downloads

82